Re-opening the long: the reason for the last exit (offering overhang) is gone — priced, closed, overallotment taken, every average reclaimed, guidance raised. Stop at $16.20 (under the MA cluster); a slide back below the $15.50 deal price would falsify the repair.
New today“The worst day in five years and retail is chanting 'opportunity of a lifetime' — biotech's lesson: when one pipeline asset blows up, the whole valuation model gets rewritten. Don't catch today's knife with yesterday's price target”
Score7/10Day move -23.9%Event ATTR-CM Phase 3 missed primary endpointMarket cap lost ~$3.2BRelative volume 8.3x
Technicals — Down 23.9% to $64.27 on 8.3x volume — the worst session since March 2021 — one candle slicing through every moving average (the 20-, 50- and 200-day all cluster near $76). RSI at 31.1 approaches oversold without being extreme, and the $75–78 gap won't fill anytime soon.
Fundamentals — The AstraZeneca-partnered Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) in ATTR cardiomyopathy missed its primary endpoint — no statistically significant reduction in CV death and recurrent events through week 140 versus placebo. ATTR-CM is a multi-billion-dollar market, and that growth curve just got erased; the approved polyneuropathy indication and the rest of the pipeline stand, but the valuation lost a pillar.
News — Jefferies and BofA both cut targets to $90 (from $113 and $111, Buys intact) the same day, and law firms have launched investigation notices. Yet StockTwits retail is euphoric — 'opportunity of a lifetime' trended. A day of institutions cutting targets while retail yells bottom.
Short-term · 1–3 weeks
NeutralSidelines
Day one of a pipeline-failure crash is never the bottom: index rebalancing, risk-desk liquidations and target cuts roll on for days. 8.3x volume says the hand-off has only started.
Entry No knife-catching; reassess after volume dries up and the target-cut wave completesStop —Target —
Long-term · months+
Neutral
The antisense platform remains a scarce technology asset with an approved-product floor; but filling the ATTR-CM hole needs new pipeline data, and rebuilding trust takes time.
AstraZeneca dialing back commercial investment
Law-firm investigations and potential class actions
A dense readout calendar keeps volatility elevated
Community Voices
StockTwits · 'Opportunity of a lifetime' — the board chants it every time a pipeline blows up; the one right call gets remembered, the nine wrong ones never come upOriginal ↗
Institutional Views
华尔街共识 · 26 analysts average $96.70 (+50% vs. spot) — a stale number that predates the trial miss and is being cut in batches
Jefferies · Target $113→$90, Buy maintained: the polyneuropathy franchise and remaining pipeline hold valueSource ↗
New today“The rival blew up in public, its own Phase 3 bloomed, and KKR's crowd wheeled in $1B — three blessings in one day. The only problem: at RSI 87, all three are in the price. Chasing here means paying for the party”
Score7/10Day move +15.1%RSI(14) 86.8Triple catalyst Rival's miss + infigratinib Ph3 win + $1B raisePosition All-time high
Technicals — Up 15.1% to $90.17, an all-time high ($91.67 intraday) on 3.7x volume, RSI at a scorching 86.8. Price sits 25% above the 20-day ($72) — an extension at record extremes. The momentum is real, but any retest will be fast and deep.
Fundamentals — Three catalysts resonating: the rival eplontersen ATTR-CM failure directly widens Attruby's moat; oral infigratinib hit all primary and key secondary endpoints in Phase 3 achondroplasia (NEJM-published) with NDA/MAA filings planned for 2026; and a $1B preferred raise led by Sixth Street, KKR and HealthCare Royalty. Commercial, pipeline and balance sheet all thickened at once.
News — TheStreet's headline said it plainly: 'BridgeBio jumps after rival heart drug fails.' The ATTR-CM competitive map was redrawn overnight — oral Attruby versus Pfizer's aging incumbent, with the gene-silencing camp down a major contender.
Short-term · 1–3 weeks
NeutralSidelines
The fundamental inflection is real and durable (competitive map, pipeline, cash), but +15% in a day at RSI 86.8 offers terrible entry odds. A textbook 'core watchlist, wait for the retest' name.
Entry A low-volume retest of $78–82 (the gap's upper rim) is the entry to want; no chasing RSI 87Stop —Target —
Long-term · months+
Accumulate
Attruby's first-mover position strengthens with a rival gone, infigratinib opens the second indication curve, and the $1B raise removes dilution suspense — the rare-disease platform's compounding structure has taken shape.
Price competition from Pfizer and remaining ATTR rivals
Infigratinib approval or launch pace disappointing
Structural costs of the preferred financing
Community Voices
StockTwits · IONS's funeral became BBIO's wedding, with the same posters crying in the morning and toasting by afternoon — biotech's zero-sum game has never been subtleOriginal ↗
Institutional Views
华尔街共识 · 24 analysts, average target $106.40 (+18% vs. spot), 1.17 — strong-buy territory
QuiverQuant · The $1B raise led by Sixth Street, HealthCare Royalty and KKR paves the commercialization runwaySource ↗
New today“Comps of +8.8% would be a victory lap anywhere else; at 42x earnings it's an accident scene. Great company and great price were always two separate questions — and the second answer is being written down in front of you”
Technicals — Down 4.2% to $912.97 on 1.5x volume, breaking the 200-day ($956.90), now at the 27th percentile of its 52-week range. RSI 34.8 is weak but not oversold, the since-May pattern of lower rebound highs remains a clean distribution structure, and next support sits near $880 (the 52-week-low shelf).
Fundamentals — June net sales +10.6%, comps +8.8% — excellent in absolute terms, but below the 10.6% expected and a clear deceleration from May's 12.5%; Canada comps of just +3.7% plus FX and gas deflation dented reported numbers. JPMorgan cut its target to $1,100 the same day. The franchise is fine; the problem is purely the multiple — 42x forward prices in 'beats forever.'
News — After a second straight month of 'in line but no upside,' profit-takers headed out. Seeking Alpha called it 'a small June swoon'; the market voted with -4.2%. Richly valued defensives are being systematically repriced.
Short-term · 2–4 weeks
NeutralSidelines
A premium name below its 200-day needs time, not hope — grinding from 42x toward 35x doesn't finish in a week. Membership renewal rates are the hole card; let the next monthly report play it.
Entry A dry-volume hammer near $880 allows a light left-side probe; no right-side trade until the 200-day ($957) is reclaimedStop $865Target $955
Long-term · months+
Neutral
The membership model is bulletproof, but today's price still pays for perfection; odds reappear only once the multiple digests below ~35x.
Continued comp deceleration triggers a multiple-and-estimate double hit
Tariffs lifting imported-goods costs
International slowdown against tough comparisons
Community Voices
StockTwits · 'I've waited three years for sub-$900' — those about to get their wish should ask why it's finally fallingOriginal ↗
Institutional Views
华尔街共识 · 39 analysts, average target $1,094 (+20% vs. spot), 1.51 rating
JPMorgan · Target cut to $1,100 — the deceleration pressures the valuation premiumSource ↗
+0.70%07-07“On the eve of its biggest rival's US listing it rallied 4.5% to greet the guest — a 7x oversubscribed SKHY isn't dilution, it's endorsement: the world's money is voting for the memory cycle. Above $880, stay in the sedan chair”
Technicals — Up 4.5% to $991.64, back at the $1,000 doorstep after a three-day recovery, RSI repaired to 50. The 50-day ($889.50) survived the pullback test; the 20-day ($1,049) is first resistance, and reclaiming it points back toward the $1,213 prior high.
Fundamentals — SKHY priced at $149, 7x oversubscribed, with Baillie Gifford and Coatue anchoring — institutions just priced the HBM cycle with $26.5B of real money. Analysts note SKHY's 5.5x forward P/E versus Micron's 6.66x, but that gap more likely closes via SKHY rising than MU falling: the demand story (HBM sold out through 2027, the Anthropic pact) is unchanged.
News — WSB mentions of 531 kept it at #1 with nearly 6,000 upvotes, a weekly high, as retail re-ignited on SKHY heat. Today's debut will directly calibrate the memory complex's near-term direction.
Short-term · 1–3 weeks
LongBullish
Holding: the oversubscribed SKHY validates sector flows, and the relative-value math skews toward upward convergence. The $880 (50-day) hard stop stands a third day — debut-week volatility rewards discipline over prediction.
Entry Hold; if the SKHY debut shakes the tape, a $900–950 retest is the add-watch zoneStop $880Target $1150
Long-term · months+
Accumulate
HBM shortage through 2027, $100B contracted revenue as the floor, deep Anthropic alignment; SKHY's listing moves global memory price discovery onto one exchange — transparency favors the leaders.
A broken SKHY debut would drag sector sentiment
A supply response at the cycle top
Peak WSB heat often precedes near-term pullbacks
Signal BacktestCumulative +0.70%price itself -3.94%profitable since 07-10
07-07Long$984.75 → open → $991.64+0.70%
Community Voices
WSB · 5,894 upvotes on 531 mentions — a board that's all nods and no fights sits closer to consensus peak than one full of arguments; enjoy it, carefullyOriginal ↗
Institutional Views
华尔街共识 · 53 analysts, average target $1,576 (+59% vs. spot), 1.14 — near strong buy
TradingKey · SKHY at 5.5x forward vs. MU at 6.66x — the debut could catalyze sector multiple convergenceSource ↗
-0.97%07-07“Up 5.7%, the elevator is back at the penthouse — 6% above the consensus target, where the sell side collectively scratches its head. Up here, a bull's best friend is the stop, not the research note”
Score8/10RSI(14) 55.9Day move +5.7%52-week position 91st percentile of rangeSpot vs. consensus target 6% above ($546.7 vs. $515.5)
Technicals — Up 5.7% to $546.72 into record-close territory, RSI a healthy 55.9, the 20-day ($525.70) just reclaimed. Up 150% YTD at the 91st percentile of the 52-week range — the trend structure is intact without froth, the most comfortable shape a momentum name can hold.
Fundamentals — The MI-series inference share story keeps compounding, with WSB mentions warming from 41 to 65. But price now sits 6% above the 60-analyst average target — further upside depends on a target-hike wave, which usually needs a fresh catalyst (earnings or a marquee customer announcement) to trigger.
News — It led megacap chips on the SMH +2.5% rebound day, forming the AI-hardware-repair troika with MU and AVGO. SKHY listing heat lifts the entire compute chain.
Short-term · 1–3 weeks
LongBullish
Holding: trend intact, RSI unstretched — but trading above sell-side targets means sentiment is doing the pushing now. Stop raised from $495 to $508 (half an ATR under the 20-day) to lock gains.
Entry Hold without adds; a $525 (20-day) retest is the reboarding zoneStop $508Target $580
Long-term · months+
Accumulate
The number-two seat in AI inference keeps solidifying, with the MI roadmap resonating with hyperscaler custom demand; the narrative discount to NVDA persists.
Trading above targets amplifies any earnings miss
NVDA price cuts or launches squeezing the share story
AI capex cycle swings
Signal BacktestCumulative -0.97%price itself +1.08%
07-07Long$552.05 → open → $546.72-0.97%
Community Voices
WSB · Mentions 41→65 — retail remembered it only after the rally; their love always runs half a beat late, though this time the trend left room on the slope for late confirmationOriginal ↗
Institutional Views
华尔街共识 · 60 analysts average $515.50 — now 6% below spot; 1.27 strong-buy rating with lagging targets
-3.15%07-07“Three days of tightrope-walking on the $390 stop, then one leap back above the 20-day — the bulls kept their dignity, but judgment day is still 7/22. Every green candle until then is just a bargaining chip in pre-trial settlement”
Score7/10RSI(14) 50.9Day move +3.2%Key level Reclaimed the 20-day ($399.60)Earnings 7/22
Technicals — Up 3.2% to $406.55, reclaiming the 20-day ($399.60) on volume and pressing the 50-day ($408.60), resolving the three-day squeeze upward. RSI 51 is neutral; the 200-day at $418 frames the pre-earnings ceiling.
Fundamentals — The delivery beat and Miami robotaxi launch still radiate warmth, amplified by high-beta torque on a chip-rally day. The $406 consensus target sits exactly at spot — the whole bull-bear valuation gap is riding on 7/22 margins and FSD numbers.
News — WSB mentions ticked up 46→57. With the spotlight diverted to chips and biotech drama, it quietly repaired its technicals while nobody watched — often a good omen.
Short-term · 1–2 weeks
LongLean bullish
Holding: the 20-day reclaim defused the breakdown, but pre-earnings upside is ridden with a frozen position. The $390 hard stop stands — an unexplained break before the print means the market knows something early.
Entry Hold, no adds, no moves before earningsStop $390Target $430
Long-term · months+
Neutral
Robotaxi moving from slides to operations is real progress, but the price embeds heavy optionality; 7/22 margins are the long-book reassessment point.
A Q2 margin miss
Robotaxi safety-incident tail risk
Durability of the European demand surge
Signal BacktestCumulative -3.15%price itself -4.41%
07-07Long$419.77 → open → $406.55-3.15%
Community Voices
StockTwits · The people calling breakdown three days ago are calling breakout today — pre-earnings technical analysis is fortune-telling; position sizing is the real religionOriginal ↗
Institutional Views
华尔街共识 · 51 analysts, average target $406.30 (right at spot), 1.77 rating — the Street stays on the fence
-11.49%07-04“Stopped out three days ago when the offering hit; today the boot dropped, underwriters swallowed the full overallotment, and price reclaimed every moving average. Re-boarding isn't embarrassing — refusing this signal just to vindicate the last exit would be”
Technicals — Up 8.8% to $18.12, a 17% premium to the $15.50 offer, reclaiming the converged 20/50/200-day cluster ($15.70–16.40) in one move. 1.6x volume confirms real demand and the offering-crash gap has fully filled — a V-shaped repair after the supply shock cleared.
Fundamentals — The offering priced at $15.50, raised $1.2B and closed on 7/9 with the overallotment fully exercised — institutions loaded up at that level. Add Q2 deliveries of 12,194 beating guidance, the full-year raise to 65–70k, and DoE loan matching funds in place: dilution bought certainty for the R2 ramp.
News — Benzinga flagged the moving-average reclaim; ts2 noted the climb back over deal price with focus on 42,441 YTD deliveries. Last week's panic supply became this week's institutional cost basis.
Short-term · 2–4 weeks
LongBullish
Re-opening the long: the reason for the last exit (offering overhang) is gone — priced, closed, overallotment taken, every average reclaimed, guidance raised. Stop at $16.20 (under the MA cluster); a slide back below the $15.50 deal price would falsify the repair.
Entry $17.2~18.3Stop $16.20Target $22
Long-term · months+
Neutral
The R2 ramp and DoE-backed capacity story now has funding certainty, but profitability remains distant; treat it as a catalyst-driven trade, not a buy-and-hold conviction.
Losing the $15.50 deal-price floor turns it into resistance
Q2 margins and the R2 ramp cadence
EV demand and tariff-policy swings
Signal BacktestCumulative -11.49%price itself +9.88%0/1 closed trades wonprofitable since 07-07
07-04Long$18.63 → closed $16.4907-08-11.49%
07-10Long$18.12 → open → $18.12+0.00%
Community Voices
StockTwits · Last week's 'dilution vampires' posts have become 'smart to raise at highs' praise — retail memory is exactly one green candle longOriginal ↗
Institutional Views
华尔街共识 · 29 analysts average $18.70 (at spot), 1.74 rating — targets get remarked as the raise digests and guidance lifts
StockTitan · 75M shares priced at $15.50 for ~$1.2B, overallotment fully exercisedSource ↗
New today“Same landmine: Ionis lost a quarter of its value, this one just a 5.7% graze — a big pharma's diversified pipeline is body armor. But armor doesn't lift the triple-average ceiling at $183; don't mistake resilience for an entry”
Technicals — Down 5.7% to $178.49 on 3x volume, breaking below the triple-average cluster near $183 — overnight, the support band became a resistance band. RSI 43.5 is soft-neutral, mid-range on the year, with no near-term structure to lean on.
Fundamentals — The Wainua ATTR-CM expansion failure removes a multi-billion-dollar growth option, but it was one option inside a sprawling oncology-respiratory-rare-disease portfolio. For Ionis it was a valuation pillar collapsing; for AstraZeneca, an option expiring worthless — the same event at two orders of magnitude.
News — The same trial data that cratered Ionis 24% sent this down 5.7% on 3x volume — among its larger single-day drops of 2026. BridgeBio's Attruby emerges as the ATTR-CM market's direct beneficiary.
Short-term · 2–4 weeks
NeutralSidelines
A defensive mega-pharma below all its averages usually grinds sideways rather than bouncing; gap repair needs a fresh catalyst. Dividend and valuation set the floor, but there's no near-term entry signal.
Entry Reassess above the $183 triple-average band; support below sits near $172Stop —Target —
Long-term · months+
Neutral
The oncology compounding machine isn't broken — ATTR-CM was one option among many; but with the growth story downshifted, a re-rating depends on the H2 oncology data cycle.
A dense readout calendar — a second miss would damage the valuation frame
Drug-pricing policy and tariff risk
Impairments on Wainua commercial investment
Community Voices
StockTwits · 'Only down 5.7%, the market doesn't care' — what the market cares about was never this failure, but how much multiple you dare pay before the next readoutOriginal ↗
Institutional Views
华尔街共识 · 31 analysts, average target $222 (+24% vs. spot), 1.27 rating
New today“The bitcoin miner announced its pivot to AI data centers and a 2GW blueprint bought a 10% pop — the land is real, the power is real, the tenant is still in the slide deck. Stories like this sell imagination; size the position by imagination's failure rate”
Score6/10Day move +10.0%Catalyst 1,200-acre powered Texas site, 2GW AI campus planNew coverage Citizens Outperform, $24 targetCatch No tenant signed yet
Technicals — Up 10% to $13.22 after an 18% intraday spike — the fade shows real supply above the 20-day ($13.70). RSI 49 is neutral, the 200-day ($12.40) anchors below, and only a $14 break exits the six-month box.
Fundamentals — The 1,200-acre powered Matagorda County site plus the pending 505MW Long Ridge gas-plant deal doubles full-energization capacity to 4.8GW — another step in the pivot from pure mining to AI/HPC infrastructure. But the 2GW campus has no signed tenant; an entire leasing cycle separates the story from cash flow.
News — Citizens initiated at Outperform with a $24 target; Strategic Bitcoin Reserve policy chatter added sector fuel, with RIOT +5% and CLSK +6% alongside. Miner-to-AI-landlord conversion is this rally's shared script.
Short-term · 2–4 weeks
NeutralSidelines
The intraday fade under the 20-day says speculation dominated the pop; bitcoin's price and tenant progress are two variables it controls neither of. The odds aren't legible.
Entry No participation until a volume-backed hold above $14 or a signed tenant landsStop —Target —
Long-term · months+
Neutral
Powered land is a real asset in the AI power famine, and the 4.8GW pipeline has option value; but the miner-to-landlord conversion needs leases, financing and execution — three proofs, none yet delivered.
A bitcoin downturn compresses cash flow and multiple at once
AI campus leasing falls short
Dilution funding the conversion capex
Community Voices
WSB · '4.8GW of power is the new oilfield' — the last crowd chanting this bought the top of the rig cycle; power stories still end with someone signing a leaseOriginal ↗
Institutional Views
华尔街共识 · 15 analysts, average target $18.10 (+37% vs. spot), 1.47 rating
Citizens · Initiated Outperform, $24 target: the HPC pivot toward hyperscale customers drives the re-ratingSource ↗
+11.97%07-02“It kept climbing on a day HK tech broadly slipped — a re-rating's hardest evidence isn't magnitude but independence. After an 18.6% week the extension is maxed; stop up to HK$105 and let the market decide which page this story ends on”
Score8/10RSI(14) 57.0Weekly +18.6%Open P&L ~+9% (opened 7/8)Tape character Re-rating day three, alone strong as tech slipped
Technicals — Up 3.7% to HK$112.00, +18.6% on the week, leading against the tape as HK tech slipped. RSI 57 has room and the 50-day (HK$117.50) is first resistance; but an 11% extension over the 20-day (HK$101.20) means retest pressure is accumulating.
Fundamentals — The three-day re-rating rests on unchanged pillars: Q1 e-commerce profit repair with flash-sale losses shrinking faster than expected, first position on the H200 access list, and banks collectively lifting China AI valuation frameworks. After +18.6% in a week, the fastest leg of the re-rating is done — earnings must take the baton.
News — In Friday's structural tape with tech broadly soft, its +3.7% shows the bid is active allocation, not sector beta. The southbound-versus-foreign tug-of-war over pricing power is the next act.
Short-term · 1–3 weeks
LongBullish
Holding (~+9% in three days): strength independent of the sector confirms the re-rating isn't done. Stop raised from HK$100 to HK$105 to bank half the gain, with the next raise past the 50-day (HK$117.50).
Entry Hold; latecomers wait for a HK$103–106 retest rather than chasing an 11% extensionStop HK$105Target HK$130
Long-term · months+
Accumulate
The cloud-plus-AI second curve just got a tangible compute catalyst, with stabilized e-commerce profits as the cushion; still 22% below the 200-day, the re-rating runway isn't spent.
H200 access policy reversals
Technical give-back after an 18.6% week
A reignited subsidy war eroding the profit repair
Signal BacktestCumulative +11.97%price itself +19.02%0/1 closed trades wonprofitable since 07-09
07-02LongHK$94.5 → closed HK$94.107-04-0.42%
07-08LongHK$99.6 → open → HK$112+12.45%
Community Voices
雪球 · From 'selling the bounce at 110' to 'this time is different' took exactly three days — stops don't change conviction; people without stops doOriginal ↗
Institutional Views
华尔街共识 · 34 analysts, average target HK$186.40 (+66% vs. spot), 1.16 — strong-buy territory
New today“Up 37% in a month and still getting UBS target hikes plus HK$100M of company buybacks — a CXO spring is built from orders, not slogans. Positions that grind from red to green are the hardest to hold; the stop raised to HK$34 will manage your hands for you”
Technicals — Up 5.6% to HK$39.14 — a second high-volume candle in the acceleration leg, +37.4% on the month. RSI at 68.7 approaches overbought, but early-trend overbought is proof of strength; HK$42 (the 52-week-high zone) is the next test, with the 20-day (HK$33.60) far below.
Fundamentals — UBS raised FY2027–29 revenue forecasts with its target going HK$49.30→51.10; the company bought back 2.72M shares for nearly HK$100M on 7/7. With WuXi AppTec's upbeat pre-announcement lighting up the CRO complex, the biologics-outsourcing utilization recovery is being validated by orders.
News — CXO has become one of the strong seams in HK's structural tape — pre-announcement beats, buybacks and foreign upgrades resonating. This position's repair from -3.3% to roughly +9% is a textbook case for patience.
Short-term · 1–3 weeks
LongBullish
Holding (~+9%): acceleration leg, institutional upgrades and buybacks in triple support. Stop raised from HK$32.50 to HK$34 (tight, just above the 20-day); at RSI near 70, no adds — and no preemptive trimming either.
Entry Hold; a low-volume dip to HK$36–37 is the add-watch zoneStop HK$34Target HK$45
Long-term · months+
Accumulate
The twin inflection of biologics-outsourcing penetration and utilization is order-verified, the darkest geopolitical hour has passed, and the multiple still sits in the lower half of its historical range.
US biosecure-legislation risk reigniting
Mean-reversion pressure after a 37% month
Order conversion and capacity ramp cadence
Community Voices
雪球 · Two weeks ago the board debated whether CXO was a value trap; today they're modeling 2028 capacity — research writes itself fast in a bull tapeOriginal ↗
Institutional Views
华尔街共识 · 17 analysts, average target HK$50.60 (+29% vs. spot), 1.15 — strong-buy territory
0.00%07-09“Yesterday we said 'wait until the insiders finish selling'; today's -7.5% counted the remaining supply for us. It took one day to slide from the hot channel into the oversold channel — AI faith is still queueing up for its beating at the hands of float”
Score5/10RSI(14) 30.8Day / week -7.5% / -22.5%Unlock 63% of shares in July's first tranche, supply ongoingChannel shift Slid from HK-hot into HK-oversold
Technicals — Down 7.5% to HK$275.20, -22.5% on the week, now 50%+ off the post-IPO high with RSI touching the oversold rim at 30.8. Relative volume has faded from 5.2x to 1.3x — selling pressure is ebbing at the margin, but so are the bids; a shrinking-volume grind hurts longer than a crash.
Fundamentals — No new fundamental negatives — this is pure float clearance: the 63% unlock supply is far from digested, and the honeymoon-era HK$877 target sits an entire lock-up away from reality. Model monetization data is the next narrative-changing variable, with no release window in sight.
News — A fifth straight down day even as HK's AI complex stays warm — the flow hierarchy persists: Alibaba and Tencent harvest the re-rating while the unlocking float digests supply alone.
Short-term · 2–4 weeks
NeutralSidelines
Restated a second day: supply shocks don't bottom on price, they bottom on exhaustion. RSI just touched 30 — unlock regimes have historically camped in the 20s for weeks.
Entry Stay out; clearance = volume under 1x, hammer lows, and a reclaimed 20-dayStop —Target —
Long-term · months+
Neutral
Still a scarce first-tier frontier-model asset, and a 50% drawdown improves the risk-reward; but an allocation case still awaits two prerequisites — the unlock cycle ending and monetization data landing.
Further unlock tranches sustaining supply
Funding dependence and burn rate
Rival model iteration speed
Community Voices
雪球 · 'Down 50%, surely that's the bottom' — bottoms aren't computed in percentages; they're defined by the last disappointed sellerOriginal ↗
Institutional Views
华尔街共识 · 18 analysts average HK$877 — an IPO-honeymoon artifact whose gap to spot is itself the warning
+4.08%07-04“The whole chip complex partied and it alone skipped the dance — yesterday's hero got borrowed to fund MU and AMD buys. Rotation isn't betrayal, but two straight days of lagging demands the question of who knows what; above the 200-day, hold and watch”
Score7/10RSI(14) 49.7Day move -0.7%Divergence SMH +2.5%, it fell aloneKey level Wrestling the 20-day at $201.40
Technicals — Down 0.7% to $202.78 against SMH's +2.5% — intra-sector rotation pulled money from the leader into MU, AMD and the SKHY trade. Still above the 200-day ($191.50) and wrestling the 20-day ($201.40); the six-day hold above the long-term line is intact.
Fundamentals — Nothing newly negative: the Kyber denial and H200 access tailwinds still work through the tape — this is short-term flow diversion. But with SKHY listed, the menu of AI-hardware exposure grows, marginally diluting the leader's scarcity premium — a structural variable worth tracking, not fearing.
News — WSB mentions cooled 264→235, slipping to #5. The AI narrative's center of gravity clearly shifted from GPUs to memory (HBM/SKHY) this week — the leader ceded the microphone for now.
Short-term · 1–3 weeks
LongBullish
Holding: lagging on a rotation day is no exit signal — the 200-day structure and the two falsified bear cases stand. Stop stays $188; three straight days of sector underperformance would trigger a rethink.
Entry Hold; no adds until the 50-day ($209) is securedStop $188Target $230
Long-term · months+
Accumulate
Still the AI compute toll collector at a three-year-low 21.7x forward; medium term, the SKHY comparison spotlights its cash-flow quality rather than dimming it.
Sustained intra-sector rotation draining flows
H200 policy whiplash
Long-run substitution from in-house silicon camps
Signal BacktestCumulative +4.08%price itself +2.63%profitable since 07-07
07-04Long$194.83 → open → $202.78+4.08%
Community Voices
WSB · The trending topic flipped from GPUs to HBM — attention is the fastest-rotating asset class; fortunately earnings don't need trending votesOriginal ↗
Institutional Views
华尔街共识 · 66 analysts, average target $313 (+55% vs. spot), 1.13 — strong-buy territory
Up 0.8%, a step from record highs with chips carrying the baton; $740 (the 20/50-day band) is retest support(Long-term: Core allocation unchanged — new highs are not a sell signal)
Up 1.7%, reclaiming the 20- and 50-day on volume — the tech repair got its follow-through; $710 flips to support(Long-term: The core AI vehicle; pullbacks are windows)
Up 1.5% with bitcoin's rewarming and reserve-policy chatter; the -30.6% YTD shows the futures decay in plain sight(Long-term: Structural roll decay makes it inferior to spot-based vehicles for the long haul)
Up 0.1%, steadying as long-duration credit breathed on cooling hike odds; RSI 35.9 still weak(Long-term: A long-end yield-locking tool where the rate path is the only variable)
Up 0.3% on 3x volume in a stabilization attempt; the warehouse-robotics name is halved YTD and 2% off its low — the buzz is bottom-fishers, not a right-side bid
